Regulatory, patent barriers may block access to new HIV prevention drug: activists

Lenacapavir, developed by U.S.-based Gilead Sciences, provides virtually 100% protection against HIV; activists slam Gilead’s patent filings, urge Indian regulators to waive requirement for local clinical trials

​Lenacapavir, developed by U.S.-based Gilead Sciences, provides virtually 100% protection against HIV; activists slam Gilead’s patent filings, urge Indian regulators to waive requirement for local clinical trials